Amorepacific Holdings teams up with HIGHER Corporation to fuse skin‑science expertise with medical‑aesthetics capabilities, aiming to launch integrated beauty‑medical products
Executive summary: Amorepacific Holdings signed a strategic investment agreement with HIGHER Corporation to collaborate on beauty and medical‑aesthetics solutions. The partnership aims to create integrated offerings that could tap into the fast‑growing medical aesthetics market and diversify Amorepacific’s revenue base.
Who is involved: Amorepacific Holdings (South Korean beauty conglomerate) and HIGHER Corporation (medical aesthetics firm), along with their respective R&D teams.
Likely next: Joint product development will begin, with prototype testing expected in the first half of 2027 and regulatory submissions planned for late 2027.
The agreement announced on July 30 2026 brings together Amorepacific’s dermatological research strengths and HIGHER Corporation’s medical‑aesthetics know‑how. By combining these capabilities, the partners seek to create products that bridge cosmetic skincare and clinical aesthetic treatments. The move reflects a broader trend of beauty firms expanding into higher‑margin medical‑aesthetics segments.
Timeline
- — Amorepacific Holdings Signs Strategic Investment Agreement with HIGHER Corporation on Beauty and Medical Aesthetics Collaboration (PR Newswire)
Analysis — what this means
Sectors affected
- Beauty and medical aesthetics
Regulatory implications
- Medical device regulations (e.g., FDA, KMFDS) may apply to any aesthetic devices developed under the partnership.
Historical parallels
- L'Oréal’s 2020 acquisition of ModiFace for AR try‑on technology
- Estée Lauder’s 2019 collaboration with DECIEM on science‑driven skincare